Pancreatic Cancer Research

ResearcherUniversidad de ZaragozaActive in the last 2 years

Roberto Pazo-Cid

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-8026-7391; OpenAlex author ID A5012440329. Sources: OpenAlex.

Their work

Papers
27 (first author 7, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
111
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 8 papers · 2026: 4 papers

Papers 27

  1. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI … First author DOI 10.1016/j.esmoop.2025.106043↗
  2. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgr… First author DOI 10.1016/j.esmoop.2026.108307↗
  3. Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial. First author DOI 10.1038/s41591-026-04705-y↗
  4. Real-World Germline Testing Patterns and Clinical Implications of HRR-Associated Germline Variants in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers18162580↗
  5. Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic… Co-author DOI 10.1016/j.esmoop.2025.105534↗
  6. Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry. Co-author DOI 10.1016/j.esmorw.2025.100116↗
  7. CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Co-author DOI 10.1016/j.xcrm.2025.102407↗
  8. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Co-author DOI 10.1080/14796694.2025.2458458↗
  9. A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial. Co-author DOI 10.1158/1078-0432.ccr-23-4026↗
  10. Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarc… First author DOI 10.1177/17588359241309828↗
  11. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  12. Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management. Last author DOI 10.3390/jcm14020367↗
  13. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre… Co-author DOI 10.1016/s1470-2045(24)00263-8↗
  14. Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer. First author DOI 10.1056/evidoa2300144↗
  15. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-lab… Co-author DOI 10.1016/s0140-6736(23)01366-1↗
  16. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA. Co-author DOI 10.1186/s13073-023-01171-w↗
  17. Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers14235993↗
  18. A Novel PiRNA Enhances CA19-9 Sensitivity for Pancreatic Cancer Identification by Liquid Biopsy. Co-author DOI 10.3390/jcm11247310↗
  19. Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography. First author DOI 10.3390/jcm10061151↗
  20. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Co-author DOI 10.1016/s2468-1253(19)30327-9↗
  21. Isolation of exosomes from whole blood by a new microfluidic device: proof of concept application in the diagnosis and monitoring of pancreatic cancer. Co-author DOI 10.1186/s12951-020-00701-7↗
  22. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cance… First author DOI 10.1200/jco.18.00089↗
  23. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. Co-author DOI 10.1186/s12885-018-5101-3↗
  24. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Co-author DOI 10.1007/s12094-016-1594-x↗
  25. Biomarkers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12094-017-1691-5↗
  26. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety … Co-author DOI 10.1016/j.ejca.2016.12.032↗
  27. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2016.271↗

Closest collaborators

The 25 strongest of 111 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa Mercade Macarulla · 15 shared papers, 2017–2026 · strength 2.56
  2. Eileen Mary O'Reilly · 6 shared papers, 2023–2026 · strength 1.18
  3. Eric Van Cutsem · 6 shared papers, 2023–2026 · strength 1.16
  4. Zev A. Wainberg · 5 shared papers, 2023–2026 · strength 0.99
  5. Andrew Scott Paulson · 5 shared papers, 2023–2026 · strength 0.99
  6. Davide Melisi · 5 shared papers, 2023–2026 · strength 0.99
  7. Tanios Bekaii‐Saab · 5 shared papers, 2023–2026 · strength 0.99
  8. Richard A Hubner · 5 shared papers, 2023–2026 · strength 0.99
  9. Shubham Pant · 5 shared papers, 2023–2026 · strength 0.99
  10. Jaime Feliú · 6 shared papers, 2022–2025 · strength 0.99
  11. Carmen Guillén‐Ponce · 8 shared papers, 2017–2026 · strength 0.95
  12. Rocio García‐Carbonero · 5 shared papers, 2023–2026 · strength 0.89
  13. Manuel M. Hidalgo · 6 shared papers, 2017–2026 · strength 0.84
  14. Sreenivasa Rao Chandana · 3 shared papers, 2023–2025 · strength 0.54
  15. Thorsten Oliver Goetze · 3 shared papers, 2023–2025 · strength 0.54
  16. Christelle de la Fouchardière · 3 shared papers, 2023–2025 · strength 0.54
  17. Igor Kišš · 3 shared papers, 2023–2025 · strength 0.54
  18. Javier Gallego-Plazas · 6 shared papers, 2017–2024 · strength 0.53
  19. Jean‐Luc Van Laethem · 3 shared papers, 2024–2025 · strength 0.52
  20. Ismael Ghanem · 3 shared papers, 2022–2025 · strength 0.52
  21. Carmen Blanco Abad · 2 shared papers, 2025–2026 · strength 0.51
  22. Alfredo Carrato · 4 shared papers, 2017–2025 · strength 0.49
  23. Hassan A. Hatoum · 2 shared papers, 2026 · strength 0.46
  24. Vincent M. Chung · 2 shared papers, 2026 · strength 0.46
  25. Enrique Aranda · 3 shared papers, 2017–2025 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.